Piper Jaffray analyst David Amsellem reiterated a Hold rating on Allergan (NYSE: AGN) today and set a price target of $164. The company’s shares opened today at $177.39.
According to TipRanks.com, Amsellem is a 1-star analyst with an average return of -1.7% and a 46.4% success rate. Amsellem covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Supernus Pharmaceuticals.
Allergan has an analyst consensus of Moderate Buy, with a price target consensus of $205.13, implying a 15.6% upside from current levels. In a report issued on July 19, Cantor Fitzgerald also maintained a Hold rating on the stock with a $180 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $256.15 and a one-year low of $142.81. Currently, Allergan has an average volume of 2.33M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States.
